Celldex Reports Upbeat Trial Results


Celldex Therapeutics Inc. (Nasdaq: CLDX) announced upbeat results from two Phase 1 clinical studies of its cancer treatment CDX-1307 sending the stock price soaring $2.69 to $11.71.

About this Entry

This page contains a single entry by published on June 1, 2009 11:11 AM.

PMI's Amended Credit Agreement Now Effective was the previous entry in this blog.

Colonial BancGroup CEO To Retire is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12